Recent News

• 11.02.2026 - Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
• 11.02.2026 - Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
• 08.19.2026 - Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
• 08.19.2026 - Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
• 08.12.2026 - Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
• 08.12.2026 - Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
• 07.22.2026 - Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
• 07.22.2026 - Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
• 07.20.2026 - Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
• 07.20.2026 - Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

Recent Filings

• 10.27.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.01.2026 - 144 Report of proposed sale of securities
• 09.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.24.2026 - 144 Report of proposed sale of securities
• 08.28.2026 - 4/A Statement of changes in beneficial ownership of securities